Sökning: "Dyskinesia"

Visar resultat 16 - 20 av 58 avhandlingar innehållade ordet Dyskinesia.

1. 16. Gene therapy by enzyme replacement for Parkinson’s disease Optimization of continuous DOPA delivery and development of a candidate vector for clinical application

   Författare :Tomas Björklund; Brain Repair and Imaging in Neural Systems (BRAINS); []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; serotonin; Parkinson’s disease; L-DOPA; dyskinesia; GTP cyclohydrolase 1; tyrosine hydroxylase; dopamine; gene therapy; enzyme replacement; gene regulation; aromatic L-amino acid decarboxylase;

   Sammanfattning : The introduction of L-DOPA pharmacotherapy revolutionized the treatment of Parkinson’s disease close to fifty years ago. Before the discovery of dopamine as a neurotransmitter and its involvement in the disease, these patients had very little aid from medication and were bound to a life without movement. LÄS MER

3. 17. Functional consequences of dopaminergic degeneration : Clinical and experimental studies using a novel stabilizer of dopaminergic systems

   Författare :Anna Ekesbo; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Neurosciences; Parkinson s disease; positron emission tomography; 6-OHDA; MPTP; dyskinesia; dopaminergic degeneration; - -OSU6162; Neurovetenskap; Neurology; Neurologi; Neurology; neurologi;

   Sammanfattning : Since the introduction of levodopa for the treatment of Parkinson's disease (PD) 30 yearsago, the emergence of motor complications, such as levodopa-induced dyskinesias (LID), hasbeen a major clinical problem in advanced stages of the disease. Clinical and preclinical studieshave revealed a number of functional changes in the dopaminergic system that may be ofimportance for the emergence of LIDs. LÄS MER

4. 18. Modeling pathophysiological aspects of Parkinson’s disease: Manipulating DA handling and alpha-synuclein expression in the nigrostriatal pathway using viral vectors

   Författare :Ayse Ulusoy; Brain Repair and Imaging in Neural Systems (BRAINS); []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Parkinson s disease; adeno-associated virus; dopamine; α-synuclein; tyrosine hydroxylase; RNAinterference; shRNA; substantia nigra; animal models; dyskinesia;

   Sammanfattning : The pathological hallmark of Parkinson’s disease is dopaminergic neurodegeneration in the substantia nigra pars compacta neurons and accumulation of α-synuclein containing aggregates in the surviving neurons. The cause of cell death in Parkinson’s disease and the involvement of α-synuclein in the pathophysiology of the disease are unknown. LÄS MER

5. 19. Striatal adaptations in experimental parkinsonism and L-DOPA-induced dyskinesia

   Författare :Tim Fieblinger; Basala gangliernas patofysiologi; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Striatum; Parkinson’s disease; L-DOPA-induced dyskinesia; ERK1 2; mGluR5; homeostatic plasticity; SPN; 2‑Photon microscopy;

   Sammanfattning : Parkinson’s disease (PD) is a neurodegenerative disorder, characterized by the loss of dopamine (DA) producing neurons in the substantia nigra pars compacta (SNc), resulting in typical motor symptoms. DA replacement with L-DOPA is the standard therapy for PD. LÄS MER

7. 20. Imaging neurochemical changes associated with Parkinson´s disease and L-DOPA-induced dyskinesia using mass spectrometry

   Författare :Elva Fridjonsdottir; Per E. Andrén; Miles Trupp; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; mass spectrometry imaging; MALDI; Parkinson´s disease; L-DOPA-induced dyskinesia;

   Sammanfattning : Parkinson’s disease (PD), caused by a loss of midbrain dopamine neurons, is the second most common neurodegenerative disease worldwide after Alzheimer’s disease. The primary treatment choice for PD is L-DOPA, the precursor for dopamine, which only affects symptoms and does not inhibit disease progression. LÄS MER